| 2.92 0.07 (2.46%) | 04-26 12:18 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 4.79  |
1-year : | 5.78 |
| Resists | First : | 4.1 |
Second : | 4.94 |
| Pivot price | 3.47 |
|||
| Supports | First : | 2.74 | Second : | 2.28 |
| MAs | MA(5) : | 2.99 |
MA(20) : | 3.68 |
| MA(100) : | 3.55  |
MA(250) : | 3.28 |
|
| MACD | MACD : | -0.5 |
Signal : | -0.4 |
| %K %D | K(14,3) : | 5.9 |
D(3) : | 6.5 |
| RSI | RSI(14): 23.5 |
|||
| 52-week | High : | 9.61 | Low : | 0.8 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ MRSN ] has closed above bottom band by 13.9%. Bollinger Bands are 18.5% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 3.22 - 3.23 | 3.23 - 3.25 |
| Low: | 2.7 - 2.72 | 2.72 - 2.74 |
| Close: | 2.82 - 2.85 | 2.85 - 2.88 |
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen development candidate. It has a strategic research and development partnerships with Merck KGaA and Asana BioSciences, LLC for the development of ADC product candidates utilizing Fleximer. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.
Thu, 25 Apr 2024
Investors Don't See Light At End Of Mersana Therapeutics, Inc.'s (NASDAQ:MRSN) Tunnel And Push Stock Down 33% - Simply Wall St
Mon, 22 Apr 2024
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mersana Therapeutics, Inc ... - The Globe and Mail
Mon, 22 Apr 2024
Mersana Therapeutics Announces Third Quarter 2021 Financial Results and Provides Business Update - The Globe and Mail
Sat, 20 Apr 2024
Shareholders in Mersana Therapeutics (NASDAQ:MRSN) have lost 80%, as stock drops 15% this past week - Simply Wall St
Thu, 04 Apr 2024
Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Thu, 29 Feb 2024
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Q4 2023 Earnings Call Transcript - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 121 (M) |
| Shares Float | 64 (M) |
| Held by Insiders | 1.3 (%) |
| Held by Institutions | 95.2 (%) |
| Shares Short | 10,130 (K) |
| Shares Short P.Month | 7,140 (K) |
| EPS | -1.49 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.31 |
| Profit Margin | 0 % |
| Operating Margin | -195.6 % |
| Return on Assets (ttm) | -38.2 % |
| Return on Equity (ttm) | -266.3 % |
| Qtrly Rev. Growth | -27.2 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0.3 |
| EBITDA (p.s.) | -1.4 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -169 (M) |
| Levered Free Cash Flow | -86 (M) |
| PE Ratio | -1.94 |
| PEG Ratio | 0 |
| Price to Book value | 9.25 |
| Price to Sales | 9.44 |
| Price to Cash Flow | -2.07 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|